The Food and Drug Administration is working to approve the Pfizer-BioNTech Covid-19 vaccine on Monday, The New York Times has reported, citing sources.
The review process could move past that date, the Times said, as paperwork and negotiations with the company remain ongoing.
The move would make Pfizer-BioNTech the first Covid vaccine to go from emergency use authorization to full FDA approval.
White House chief medical advisor Dr. Anthony Fauci told the Associated Press on Aug. 8 that he hoped vaccines would start receiving full approval “within the month of August,” adding that full approval would lead more companies and schools to mandate vaccines.
U.S. companies have tightened vaccine rules for employees as Covid cases have spiked across the country in recent weeks, and some cited full approval from the FDA as part of the decision-making process.
More than 203 million doses of the Pfizer-BioNTech vaccine have been administered nationwide, fully immunizing more than 91 million people in the U.S., according to CDC data as of Friday, Aug. 20.
